HBV messenger RNA (mRNA) is a strong predictive marker for HBeAg and HBsAg loss during antiviral treatment with nucleoside/nucleotide analogues (NUCs) in patients with chronic hep…
F van Bömmel, A Bartens, A Mysickova, A Brodzinski, B Fülöp, J Hofmann, D Krüger, T Berg, A Edelmann · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Treatment with NUCs can completely suppress HBV DNA levels in most patients, however there are few markers for the prediction of long term response. We studied the association of HBeAg and HBsAg loss with serum levels of circulating full-length (fl) and truncated (tr)HBV mRNA before and during NUC treatment. Methods: For specific detection and quantification of fl and trRNA species, two step real-time reverse transcription PCRs were developed (detection limit 450 and 600 copies/mL, respectively). 67 patients (45 HBeAg positive, mean HBV DNA level 7.6±8[9–2.8] log10copies/mL) receiving either tenofovir (TDF…
